BIO Asia-Taiwan 2026 Targets Global Capital for 27 Biotech Startups

The summit at the Taipei Nangang Exhibition Center shifts focus toward precision investment, a model where venture funds actively shape companies rather than passively waiting for deal flow. Jo Shen, Vice Chair of the Taiwan Bio Industry Organization, notes that this transition forces startups to align more closely with the specific market needs identified by global institutional investors. The event features a keynote by BroadVision founder Pehong Chen, who will address the impact of AI on shortening traditional decade-long drug development cycles.

As major pharmaceutical companies scramble to offset patent cliffs, they are increasingly looking to Asia for external innovation. This shift has bolstered the local landscape, supported by Taiwan's recent Regenerative Medicine Dual Acts and the government’s "Healthy Taiwan" initiative. Of the 27 startups presenting roadshows, 15 focus on pharmaceuticals while 12 specialize in medical devices, many backed by substantial clinical data. The summit’s panels include representatives from Raymond James Financial, DCI Partners, and Medtronic, providing a direct pipeline between regional research and global capital markets.